These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10404342)

  • 41. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
    Entenza JM; Caldelari I; Glauser MP; Moreillon P
    J Antimicrob Chemother; 1999 Dec; 44(6):775-86. PubMed ID: 10590278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group.
    Plouffe JF
    Diagn Microbiol Infect Dis; 1996 May; 25(1):43-5. PubMed ID: 8831044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
    Lacy MK; Lu W; Xu X; Tessier PR; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1999 Mar; 43(3):672-7. PubMed ID: 10049286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
    Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
    J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
    Flatz L; Cottagnoud M; Kühn F; Entenza J; Stucki A; Cottagnoud P
    J Antimicrob Chemother; 2004 Feb; 53(2):305-10. PubMed ID: 14729741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
    Peric M; Lin G; Clark CL; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2002 Jul; 50(1):95-100. PubMed ID: 12096012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
    Onyeji CO; Bui KQ; Owens RC; Nicolau DP; Quintiliani R; Nightingale CH
    Int J Antimicrob Agents; 1999 Jul; 12(2):107-14. PubMed ID: 10418754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Epidemiological analysis of Streptococcus pneumoniae in Gifu prefecture].
    Matsukawa Y; Yamagishi Y; Mikamo H; Sawamura H; Matsubara S; Yamaoka K; Asano Y; Ishigo S; Suematsu H; Mutou T; Teraji M; Hashido H; Terada H; Saeki H; Miyabe T; Tanaka K; Watanabe K; Akita S; Okada M; Takemoto Y; Sakuma T
    Jpn J Antibiot; 2010 Jun; 63(3):224-41. PubMed ID: 20976879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L; de Andrade C; Dalla Costa T
    Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
    Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
    Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of levofloxacin against gram-positive bacteria.
    Montanari MP; Mingoia M; Marchetti F; Varaldo PE
    Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
    Trampuz A; Wenk M; Rajacic Z; Zimmerli W
    Antimicrob Agents Chemother; 2000 May; 44(5):1352-5. PubMed ID: 10770776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.
    Ibrahim KH; Hovde LB; Ross G; Gunderson B; Wright DH; Rotschafer JC
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):265-71. PubMed ID: 12493174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Isolation-frequency and antibiotic susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa isolated in regional core hospitals in the Nagaoka district of Niigata Prefecture (changes for 3 years)].
    Iwashima A; Sato K; Kiguchi T; Yamaguchi M
    Jpn J Antibiot; 2004 Feb; 57(1):105-17. PubMed ID: 15116575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.